Skip to content

US · RDNT · MEDICAL - DIAGNOSTICS & RESEARCH

RadNet, Inc. (RDNT) intrinsic value and stock valuation

$69.71as of 2026-11-21 · Mkt cap 5.69B

Data updated · price as of 2026-11-21

Strongly overvaluedIC value is more than 50% below the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

RadNet, Inc. DCF and intrinsic value

InvestorsCraft values RDNT with the Chepakovich two-stage DCF model — currently rated strongly overvalued. How the model works · Run your own DCF prefilled from RDNT’s statements →

RadNet, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Medical - Diagnostics & Research Los Angeles, CA 90025 radnet.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$2.04B+13.7% 5y CAGRd
20112025
Net income
-$-18.65M
20112025
Free cash flow
$85.6M-4.6% 5y CAGRd
20112025
Total equity
$1.36B+39.3% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$2.04B$1.83B$1.62B$1.43B$1.32B
Operating income$90.8M$104.6M$98.7M$46.4M$82.6M
Net income-$-18.65M$2.79M$3.04M$10.7M$24.7M
EPSd-$-248.04K$37.3K$47K$185.8K$462.9K
Operating cash flow$298.8M$233M$220.9M$146.4M$149.5M
Capital expenditure-$-213.25M-$-188.07M-$-176.6M-$-249.41M-$-220.69M
Free cash flow$85.6M$45M$44.3M-$-103M-$-71.2M
Total assets$3.76B$3.29B$2.69B$2.43B$2.06B
Total debt$1.86B$1.73B$1.49B$1.51B$1.4B
Net debt$1.09B$988.8M$1.15B$1.39B$1.26B
Total equity$1.36B$1.13B$813.4M$491.5M$346.2M
Cash and short-term investments$767.2M$740M$342.6M$127.8M$134.6M
Income statement
20252024202320222021
Revenue$2.04B$1.83B$1.62B$1.43B$1.32B
Cost of revenue$1.95B$1.58B$1.4B$1.26B$1.12B
Gross profit$90.8M$249.1M$221.4M$165.7M$191.8M
Research and development expenses$0.00$0.00$0.00$0.00$0.00
Selling, general and administrative expenses$0.00$0.00$0.00$0.00$0.00
Other expenses$0.00$144.5M$122.7M$119.4M$109.3M
Operating expenses$0.00$144.5M$122.7M$119.4M$109.3M
Cost and expenses$1.95B$1.73B$1.52B$1.38B$1.23B
Interest income$0.00$0.00$0.00$0.00$0.00
Interest expense$69.9M$79.9M$64.5M$50.8M$48.8M
Depreciation and amortization$152.1M$137.8M$189.5M$184.7M$170.7M
Ebitda$254M$262.6M$292.8M$278.5M$278.4M
Operating income$90.8M$104.6M$98.7M$46.4M$82.6M
Total other income/expenses, net-$-58.9M-$-59.76M-$-59.89M-$-3.39M-$-23.68M
Income before tax$31.9M$44.9M$38.8M$43M$58.9M
Income tax expense$14.9M$6.03M$8.47M$9.36M$14.6M
Net income-$-18.65M$2.79M$3.04M$10.7M$24.7M
Weighted average shares outstanding$75.2M$73M$63.6M$56.3M$52.5M
Weighted average diluted shares outstanding$75.2M$74.8M$64.7M$57.3M$53.4M
Balance sheet
20252024202320222021
Cash and short-term investments$767.2M$740M$342.6M$127.8M$134.6M
Net receivables$212.9M$227.7M$189.1M$185.3M$140.5M
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$1.03B$1.02B$579.3M$367.2M$324.3M
Property, plant and equipment, net$3B$1.33B$1.2B$1.17B$1.07B
Goodwill and intangible assets$1.06B$792M$770.1M$783.9M$570.4M
Long-term investments$130.3M$104.1M$92.7M$57.9M$42.2M
Total non-current assets$2.73B$2.27B$2.11B$2.07B$1.73B
Total assets$3.76B$3.29B$2.69B$2.43B$2.06B
Accounts payable$153.2M$96.5M$122.9M$102.7M$86.5M
Short-term debt$87.4M$81.3M$74M$70M$76.6M
Deferred revenue$7.27M$3.29M$4.65M$4.02M$10.7M
Total current liabilities$586.8M$479.7M$437.5M$466.7M$374.8M
Long-term debt$1.77B$1.65B$1.42B$1.44B$1.32B
Deferred revenue, non-current$0.00$0.00$0.00$0.00-$-195.69M
Total non-current liabilities$1.82B$1.67B$1.44B$1.48B$1.34B
Capital lease obligations$768.9M$712.6M$661.1M$661.7M$643.1M
Total liabilities$2.4B$2.15B$1.88B$1.94B$1.71B
Common stock$10K$10K$10K$10K$10K
Retained earnings-$-95.44M-$-76.78M-$-79.58M-$-82.62M-$-93.27M
Accumulated other comprehensive income (loss)$4.88M-$-9.06M-$-12.48M-$-20.68M-$-20.42M
Total equity$1.36B$1.13B$813.4M$491.5M$346.2M
Total investments$130.3M$104.1M$92.7M$57.9M$42.2M
Total debt$1.86B$1.73B$1.49B$1.51B$1.4B
Net debt$1.09B$988.8M$1.15B$1.39B$1.26B
Cash flow statement
20252024202320222021
Net income$46.8M$38.8M$30.3M$33.6M$44.3M
Depreciation and amortization$152.1M$198.4M$189.5M$184.7M$170.7M
Stock-based compensation$54.6M$29.8M$26.8M$23.8M$25.2M
Change in working capital-$-9.75M-$-56.49M-$-40.27M-$-58.7M-$-92.13M
Accounts receivable-$-9.56M-$-21.77M$2.65M-$-30.08M-$-5.89M
Inventory$0.00$0.00$0.00$0.00-$-87.67M
Accounts payable$52.4M$37.1M$15.1M$49.8M$9.91M
Net cash provided by operating activities$298.8M$233M$220.9M$146.4M$149.5M
Investments in property, plant and equipment-$-213.25M-$-188.07M-$-176.6M-$-249.41M-$-220.69M
Acquisitions, net-$-133.42M-$-45.16M-$-24.95M-$-1.44M-$-1.44M
Net cash used for investing activities-$-343.87M-$-233.07M-$-201.47M-$-246.95M-$-221.51M
Common stock issued$5.45M$218.4M$245.8M$290K$490K
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$72.2M$398M$195.6M$93.7M$104.7M
Net change in cash$27.2M$397.5M$214.7M-$-6.77M$32.6M
Cash at end of period$767.2M$740M$342.6M$127.8M$134.6M
Operating cash flow$298.8M$233M$220.9M$146.4M$149.5M
Capital expenditure-$-213.25M-$-188.07M-$-176.6M-$-249.41M-$-220.69M
Free cash flow$85.6M$45M$44.3M-$-103M-$-71.2M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About RadNet, Inc.

        RadNet, Inc. operates as a prominent healthcare services company specializing in outpatient diagnostic imaging across the United States. Their comprehensive offerings span a broad spectrum of advanced imaging techniques, including magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), nuclear medicine, mammography, ultrasound, and general diagnostic radiology, along with various specialized procedures. Beyond direct patient services, the company also plays a significant role in developing and marketing specialized computerized systems for the diagnostic imaging sector, such as picture archiving communication systems (PACS) and associated support. Furthermore, RadNet is at the forefront of integrating artificial intelligence (AI) solutions, designing and deploying AI suites to augment radiologist interpretation, particularly in mammography, and extending these AI capabilities to lung and prostate cancer diagnostics. As of December 31, 2021, its operational footprint included ownership and management of 347 centers situated across seven states: Arizona, California, Delaware, Florida, Maryland, New Jersey, and New York. Established in 1981, the company maintains its headquarters in Los Angeles, California.

        CEO
        Howard G. Berger
        Employees
        8.84K
        Beta
        1.36

        Included in

        Explore

        Frequently asked questions

        What is the intrinsic value of RadNet, Inc. (RDNT)?

        RadNet, Inc. (RDNT) is currently strongly overvalued based on the InvestorsCraft IC model — IC value is more than 50% below the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is RDNT undervalued?

        RDNT trades at a price of $69.71 (Nov 21, 2026): strongly overvalued — IC value is more than 50% below the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.